Patents

US 10292983 B2: Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Granted
2019-05-21
Filed
2017-08-02 application 15667004
Type
Utility · 22 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Use of oxymethylene aryl GPR119 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.

Source: PVGPATDIS, file of 2026-04-10 (ipg190521.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
CymaBay Therapeutics, Inc. 43 patentsUS company or organizationNewark, CACymaBay Therapeutics, Inc. Form D issuer EXACT high confidence: identical full name and state
CYMABAY THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
Charles A. McWherterNewark, CA34PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K31/506PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

No recorded assignments or security interests on file for this patent.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.